• Sproutly Canada reaches company milestone with its first completed harvests of premium quality, small-batch cannabis
• The company offers the world’s first natural, truly water-soluble cannabis solution made with bio-natural oils through subsidiary Infusion Biosciences
• The Canadian cannabis beverage market is estimated to reach up to $4.4 billion by 2024

Sproutly Canada Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G) envisions a year of growth and expansion through its focus on cannabis beverages made using a revolutionary process featuring water-soluble ingredients.

Since going public in July 2018, with a focus on its goal of becoming a global competitor in the cannabis beverage and edibles realm, Sproutly has reached a significant milestone at its production facility in Toronto, called Toronto Herbal Remedies. Notably, the company completed its first two harvests of its premium quality, small-batch cannabis. These batches produced “highly efficient yields for an initial grow,” according Bryan Semkuley, president of Sproutly Canada. If the production results of these initial high-quality batches are replicated across all 12 of Toronto Herbal Remedies’ flowering rooms, the company will be able to radically increase its production capacity (http://ibn.fm/vKX0v).

In developing the world’s first natural, truly water-soluble cannabis solution made with bio-natural oils, Sproutly Canada is positioned to revolutionize the cannabis beverage and edibles market. By partnering with already established local and global consumer brands, the company hopes to utilize its partners’ existing customer bases to increase widespread consumer exposure to this technological breakthrough, achieving greater market penetration.

The Canadian cannabis market has been growing steadily as waves of legalization have been moving around the world, and it is estimated to be an $8.7 billion market by 2024. Growing steadily in its wake is the lesser known but ultimately promising Canadian cannabis beverage market, which is estimated to reach up to $4.4 billion by 2024, without factoring in an additional market boon created by a demand for naturally water-soluble cannabis beverages (http://ibn.fm/33Gzt). In this sense, Sproutly is well-positioned to penetrate that market through its acquired company, Infusion Biosciences, creator of the world’s first naturally water-soluble cannabis.

This cannabis beverage represents a “paradigm shift” in the world of cannabis products in regards to delivery and consumption. The product (http://ibn.fm/xNz9e) is touted as “predictable,” taking fewer than five minutes to produce effects and less than 90 minutes to wear off. It is comparable in its effects to smoking and vaping; discrete in its odorless and smokeless useability; versatile, with many end-user applications; and “precise” in its dosage, with the “ability to deliver a measurable amount of cannabis.”

With the Canadian cannabis beverage and edibles market preparing for potential legalization in 2019, Sproutly is anticipating a strong year of expansion in its pursuit of becoming a top supplier of water-soluble cannabis solutions and bio-natural oils.

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF

• Ukraine’s Ministry of Defense has developed plan to transfer key parcel of land to Black Iron for its Shymanivske iron ore deposit
• Black Iron is building a world class, high-value, low net cost project offering an ultra-high-grade iron ore concentrate
• Strong economic returns expected to be generated by the Shymanivske iron ore deposit reinforce this unique investment opportunity
• Shymanivske offers strategic location with underdeveloped resources and close proximity to target markets in Europe, the Middle East and Asia

Canadian iron ore exploration and development company Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) continues to make solid progress advancing its 100 percent owned Shymanivske iron ore deposit located in Kryvyi Rih, Ukraine. Black Iron recently announced positive momentum in its search for a parcel of land suitable for the company’s processing plant, tailings and waste rock associated with the Shymanivske project (http://ibn.fm/0cYCx).

In a recent news release, Black Iron noted that Ukraine’s Ministry of Defense (“MOD”) has developed a plan to transfer the parcel of land outlined in the company’s re-scoped Preliminary Economic Assessment (“PEA”) to Black Iron, pending final discussions that include a compensation package to cover replacement and relocation of MOD facilities. The land parcel is owned by Ukraine’s central government and is being used by Ukraine’s MOD for training purposes, per the release.

Continuing supply side shortages and a price surge in the world’s iron ore market that followed the January 25 disaster at Vale SA’s Brumadinho tailings dam, which left some 300 dead or missing and prompted shutdowns at a dozen other Vale SA properties, will be felt for some time, Bloomberg reports (http://ibn.fm/mcQnh). On March 15, a Brazilian court ordered Vale SA to halt production at another of its iron ore mines, further reducing the company’s output capacity (http://ibn.fm/hQUe7). Even with a potential restart of the mining operations, prices are expected to remain elevated, as Reuters noted in a February 18 article (http://ibn.fm/YfJav). As part of a recent Northern Miner podcast (http://ibn.fm/Py3JV), Black Iron’s CEO discussed this, as well as developments with Black Iron’s Shymanivske iron ore project in Ukraine.

Benchmark iron ore prices are holding in the mid $80 per tonne range, which is well above the long-term $62 per tonne used in Black Iron’s PEA and is estimated with an after-tax unlevered IRR of 36 percent and NPV of $1.7 billion using a 10 percent discount rate. Black Iron recently reaffirmed economic projections for its Shymanivske project in a news release (http://ibn.fm/w9w0q), noting that the premium 68 percent iron pellet feed product that Black Iron plans to produce is expected to sell for a significantly higher price than benchmark iron ore for at least the next two to three years.

“This parcel of land (proposed by Ukraine MOD) is suitable from a social and environmental standpoint, and its close proximity to the Shymanivske ore body makes it a highly economic choice to minimize the cost incurred for hauling ore and waste,” Black Iron emphasized in its news release announcing the proposed land transfer. “This land is also located well away from any communities and is surrounded by operating iron ore mines owned by ArcelorMittal and Metinvest.”

Black Iron intends to build its Shymanivske project in two phases, taking advantage of its proximity to rail, power, ports and skilled labor to reduce the upfront capital and time required to generate cash flow (http://ibn.fm/m51Tq).

The technical and scientific contents of this article have been prepared under the supervision of and have been reviewed and approved by Matt Simpson, P.Eng., CEO of Black Iron, who is a Qualified Person as defined by NI 43-101.

For more information, visit the company’s website at www.BlackIron.com

NOTE TO INVESTORS: The latest news and updates relating to BKIRF are available in the company’s newsroom at http://ibn.fm/BKIRF

• Company owns, operates and charters diversified fleet of carriers and tankers
• Grindrod conducts business under two brands that have earned a positive reputation for quality and standards since 1910
• Company provides training for shore- and offshore-based sectors of trade through accredited Grindrod Shipping Training Academy
• 2018 saw revenues of $319 million and a gross profit of $11.1 million

International shipping company Grindrod Shipping Holdings Ltd. (NASDAQ: GRIN) has roots dating back to 1910 in South Africa. Now based in Singapore, with offices around the world, the company owns and operates a diversified fleet, which currently consists of 25 owned dry-bulk carriers, seven long-term chartered-in dry-bulk carriers, 12 owned tankers and three long-term chartered-in tankers.

Grindrod Shipping manages the majority of its fleet in-house and trades globally under two key brands:

• Island View Shipping (IVS), founded in 1976 and acquired by GRIN in 1999, ships dry-bulk cargo such as minerals, coal, ores and agricultural products. IVS ships between 12 and 14 million metric tons every year across the globe.
• Unicorn Shipping began in South Africa in 1910 and relocated from London to Singapore in 2010. The brand has developed a high reputation for quality and standards as it ships liquid chemicals and clean petroleum products along the Southern African coast, as well as East and West Africa. Customers include Shell, Chevron, Engen, Total, SASOL, PetroSA and BP.

GRIN commercially and technically manages the majority of the fleet. The in-house management provides cost control and ensures the high-quality reputation GRIN has built over the past century. The management of the fleet falls on the company’s technical department, which is made up of experienced and qualified managers, including six master mariners and 10 Class 1 marine engineers.

In addition to managing the fleet, the technical department also runs the Grindrod Shipping Training Academy (http://ibn.fm/iP48X), which has been in operation since 1975 and is accredited by SAMSA (South African Maritime Safety Authority). The academy has provided training for shore- and offshore-based sectors of trade since its beginning and is able to tailor-make courses to fit the needs of its students.

In 2018, the company listed on the Nasdaq under ticker symbol ‘GRIN’ and on the Johannesburg Stock Exchange under ticker symbol ‘GSH’. The company reported revenues of $319 million and a gross profit of $11.1 million last year (http://ibn.fm/cRjPh).

For more information, visit the company’s website at www.GrinShipping.com

• New analysis by Cowen & Co. sees market for CBD products in the U.S. reaching $16 billion by 2025
• Dispensaries and health care practitioners included in expanded markets for ETST’s CBD line under new distribution agreements
• Cowen & Co. research projects that cannabis-based products will reach 10 percent of U.S. adults by 2025

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, is expanding its full-spectrum cannabidiol (CBD) product distribution in wider markets as a new study by Cowen & Co. sees cannabis products reaching $16 billion in the U.S. by 2025 (http://ibn.fm/k7QKt). ETST’s larger market includes pharmacies, dispensaries, health care practitioners, athletic clubs, clinics and chiropractors throughout the United States (http://ibn.fm/WhXk1).

Cowen & Co.’s research shows that 6.9 percent of Americans say they are already using CBD. A January survey of 2,500 adults found that CBD use is highest among adults aged 18 to 34. Tinctures (liquid extracts) dominate the market and were named by 44 percent or respondents, followed by topicals at 26 percent, then capsules and beverages.

“This initial response piqued our interest considerably, as it was much higher than we would have suspected,” analyst Vivien Azer said in a news release. As a result, Cowen sees CBD use growing to 10 percent of U.S. adults, or 25 million consumers, by 2025, implying a $16 billion market opportunity, as noted by Azer.

ETST has reached agreements with CannaBiz and Desert Sun Distribution to sell its line to chiropractors, dispensaries, pharmacies, health care practitioners, athletic clubs and clinics in the United States, providing deeper reach into the market (http://ibn.fm/BUrRx). In a news release, ETST Chief Sales Officer David Burbash said, “We see tremendous synergy between our CBD line and the health care practitioner and pharmacy spaces.” ETST is also increasing the size of its sales team.

ETST’s full-spectrum cannabinoids offer analgesic pain relief and anxiety reduction, per company marketing material. ETST offers cannabinoids in the form of soft gels, tablets, liquids and other forms classified as food-based and permissible in all 50 states and some 40 countries.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• Lung cancer is one of the most prevalent and deadly cancers worldwide. Genprex aims to develop cutting-edge gene therapies to improve outcomes, which have not changed significantly in the past 25 years despite radical advances in drug development and novel therapeutic standards.
• Genprex holds a portfolio of 30 issued and two pending patents covering technologies and targeted molecular therapies, all exclusively licensed from University of Texas MD Anderson Cancer Center. Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who otherwise would not benefit from these important cancer therapies, or who have become resistant to them.
• Genprex had a cash position of $10.3 million as of September 30, 2018.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex.

For more information, visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• ChineseHempOil.com Inc.’s consumer product line has been rebranded under the new ‘opt’ brand
• CEO Warren Wang sees potential to uplist to the NYSE or Nasdaq Small Cap Market as company reaches up to $10 million in annual volume
• Subscription revenues for premier financial information website targeting Chinese-speaking investors increased by 40 percent year-over-year

ChineseInvestors.com Inc. (OTCQB: CIIX), developer of a proprietary financial news media and content platform providing information to the global Chinese-speaking community, is following a promising game plan that includes consolidation of the its domestic consumer sites into a single channel to provide a one-stop shop for consumers weary of searching the world wide web. CIIX CEO Warren Wang said in a news release that a rebranding of its subsidiary, ChineseHempOil.com Inc., under the company’s new ‘opt’ brand will offer consumers in the United States a wide variety of premier CBD-infused product lines (http://ibn.fm/i25sW).

Consumers should visit www.365CWC.com to find the latest ‘opt’ brands, which currently include two lines: opt Hemp and opt2mist (http://ibn.fm/D4Xfd). The opt Hemp line includes gummies, oils, soft gels and cosmetics. Additional hemp-derived CBD products are in development. The company’s opt2mist is a spray-vitamin line of products in development that will also offer full-spectrum, hemp-derived CBD-infused formulas.

“The unification of our domestic consumer products under the opt brand is a step in the right direction to building optimal brand recognition as we continue to roll out our new industrial, hemp-infused CBD products and other health and wellness products, such as the opt2mist sprays, throughout 2019 and beyond,” Wang said in the news release.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational services in Chinese language character sets; consultative services to smaller private companies considering going public; and advertising and public relations support services.

Wang, who founded ChineseInvestors.com in 1999 and has been at the helm ever since, is enthusiastic about the company’s path forward. In an interview on MoneyTV with Donald Baillargeon, Wang shared that he intends for the company to uplist to the New York Stock Exchange or Nasdaq Small Cap Market as it reaches up to $10 million in annual volume (http://ibn.fm/SxpAf).

“I’m pretty confident that we will see profitability and revenue growth in the next three to five years,” Wang said in the interview. “Our other goal is uplisting to the New York Stock Exchange (NYSE) or to Nasdaq because we are looking at an acquisition, and we are looking for revenue of $6 million to $10 million in the next three to five years. I think we will definitely qualify for NYSE or Nasdaq on the small cap side.”

The company recently announced its financial results for the second quarter of fiscal year 2019, pinpointing several important accomplishments. A revenue increase of more than 50 percent year-over-year is one of the key milestones presented in a January 22, 2019, news release (http://ibn.fm/0lRlt). One of the biggest drivers for the excellent financial performance was the increase in hemp and CBD sales revenue. Year-over-year, hemp and CBD sales revenues were up by eight percent, while subscription revenues for the premier financial information website targeting Chinese-speaking investors also increased by 40 percent year-over-year.

ChineseInvestors.com is looking forward to an even stronger performance in the upcoming months, as noted by Wang. He added, “As we leverage the momentum already in place, we look forward to having an even stronger second half for FY 2019.”

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• Launch of multilingual, cross-border, Brazil-China e-commerce trade platform BOAPIN expected in first quarter of 2019
• Exclusive agreement signed with Brazilian Trade Organization, whose 7,500 members may enlist as paid subscribers to BOAPIN platform
• Pacific Software’s strategic IBM working relationship leverages industry-leading Hyperledger blockchain technology and applications

Pacific Software Inc. (OTC: PFSF), an emerging business development technology innovator, is closing in on the launch date of BOAPIN, the company’s proprietary e-commerce platform designed to improve product traceability and deliver much-needed cross-border trade solutions to global subscribers. Pacific Software anticipates that its new blockchain-based trade platform will be able to register new buyers and sellers within the first quarter of 2019, according to a news release (http://ibn.fm/XQOZS).

The platform caters to the evolving needs of an international economy with features such as product certification, marketing, logistics, a commodities search/match interface, trade finance and customs clearance, multilingual communications and cross-border payment solutions. BOAPIN is being developed as a digital, blockchain-supported e-commerce website that will initially link Brazilian agricultural suppliers to China.

“As global economies explore strategies to improve cross-border data infrastructure, Pacific Software is creating smart contract technology that integrates important functionalities for seamless global supply chain management,” Pacific Software CEO and Chairman Harrysen Mittler stated in the release.

BOAPIN is described as an essential element of a new partnership that Pacific Software has signed with China and FIERO, a leading Brazilian trade association focused on developing and promoting the economy of Rondônia, a regional state within Brazil (http://ibn.fm/2vCDM). More than 7,500 FIERO members will soon be able to subscribe to BOAPIN and take advantage of the platform in a bid to expand their sales territory and ensure trade sustainability.

BOAPIN’s inner strength lies in its use of IBM’s Hyperledger Blockchain Backend as a Service (BaaS) infrastructure. The platform tracks, records and stores digital product information by integrating blockchain components that are accessible via a variety of channels linked into the Internet of Things (IoT). By linking to the IoT, the platform is expected to be able to gather valuable product data and make complex supply chains more manageable and safer for all (http://ibn.fm/eCz8b).

It’s not uncommon nowadays for the public to be notified of a product recall. IBM notes that the use of blockchain technology can reduce the cost of the average product recall by up to 80 percent, according to an article published by Forbes (http://ibn.fm/cvyuF). IBM’s Food Trust system uses blockchain to connect participants through a transparent, permanent and shared record of food origin details, processing data, shipping details and more. This is vital, as food fraud costs the global food industry between $10 billion and $15 billion annually, according to the article.

In an annual shareholder letter issued on January 31, Mittler said that, in 2018, Pacific Software achieved its goal of creating a cross-border e-commerce trade platform, and he expects the company to maintain an aggressive pace as it seeks to further expand into the commercial markets of Brazil and China (http://ibn.fm/js3PZ).

For more information, visit the company’s website at www.PacificSoftwareInc.com

NOTE TO INVESTORS: The latest news and updates relating to PFSF are available in the company’s newsroom at http://ibn.fm/PFSF

• Green Hygienics Holdings has innovated cannabis cultivation through its use of organic, pesticide-free aeroponic cultivation technology
• The company entered escrow to purchase the 824-Acre Potrero Ranch property near San Diego, California
• This tract of land offers ideal growing conditions for cannabis cultivation, as well as several other related business opportunities

Green Hygienics Holdings Inc. (OTCQB: GRYN), a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational markets, anticipates a lucrative property acquisition, which could expand its yield capabilities and overall market presence. This 824-acre tract of land, the Potrero Ranch property, is located near San Diego, California, and offers impressive growing potential for the company, which has more than 25 years of experience in agricultural science and innovation.

The Potrero Ranch property boasts expansive grassland pasture surrounded by a curtain of neighboring mountains, providing a natural privacy screen. The other natural elements of the area, including a plentiful water supply, rich soil and altitude, are all conducive to achieving the company’s goal of growing and marketing premium-grade cannabis (http://ibn.fm/p3G8P).

Aside from its natural landscape, the property’s existing infrastructure is also valuable. Multiple outbuildings dot the expansive property, each equipped with “triple phase power, water, and gas services.” These buildings are “ideal for greenhouses or storage,” and the main building features “a large built-in cooler.”

Green Hygienics Holdings Vice President of Business Development Matt Dole noted the lucrative potential of this new property. In a news release, he stated, “Given that there is the potential to harvest 1,200 to 1,500 pounds of hemp per acre, we can produce two crops per year, and the price of hemp is at an average of $50 dollars per pound, this initiative has the potential to produce significant revenues for the Company.” Dole further recognized the enormous potential of this property acquisition to “provide a base of operations for several other equally exciting initiatives.”

Green Hygienics Holdings has already created a name for itself in the burgeoning cannabis industry through its focus on advancing the methodology of cannabis cultivation. The company executes each stage of its aeroponic growing system with precision, giving plants a precise amount of nutrients and water delivered directly to their roots through a fine mist in a controlled environment. This precision allows the company to dramatically reduce waste and crop spoilage, enhancing yield figures and allowing the product to remain organic and fully pest-free. Green Hygienics Holdings utilizes technology that conserves natural resources, using up to 95 percent less water than competitors.

As an established leader in the field, Green Hygienics Holdings anticipates continued growth through its anticipated land acquisition and remains laser focused on maintaining the highest standards of cultivation in order to produce premium-quality cannabis.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• MCOA wants to extend its CBD-infused hempSMART brand into Asia and Europe using capital raised from the sale of common stock
• March launch of hempSMART in the U.K. kicks off planned entry of the brand into Europe
• hempSMART campaign in U.S. includes participating in high-level events such as the Super Bowl and pre-Academy Awards festivities

Marijuana Company of America Inc. (OTCQB: MCOA) is raising the profile of its hempSMART subsidiary in the United States and is planning an expansion of the brand into Asia and Europe. The company intends to use $10 million in new capital that it plans to raise from the sale of common stock to fund these expansion efforts. MCOA has already filed a form S-1 with the SEC to begin the registration process (http://ibn.fm/GixtI).

MCOA has also begun to unveil the hempSMART brand in the United Kingdom prior to entering the continent of Europe, including scheduling a pre-launch event in London this month. In addition, Marijuana Company of America has established a regional office, a customer service team and a distribution center in London. Field marketing and training have already been completed for hempSMART UK (http://ibn.fm/WTcHc).

In a news release, MCOA CEO Donald Steinberg said, “As legislation continues to evolve and the demand for hemp-derived CBD products grows internationally, we will continue to launch our hempSMART associate marketing model and products to additional countries across the world.”

MCOA conducts product research and development of legal hemp-based consumer products containing CBD under the brand name hempSMART. Focused on general health and well-being, the company also conducts an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD. In addition, MCOA is expanding its business into ancillary areas of the legalized cannabis and hemp industry as this segment matures and develops.

To further raise its brand profile in the States, MCOA participated in high-awareness events at Super Bowl LIII and prior to this year’s Academy Awards. During those activities, athletes, celebrities, actors, musicians and other attendees received samples of hempSMART products (http://ibn.fm/BLYYc).

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Shoppers Drug Mart is now the exclusive direct-to-patient online provider of FlowrRx products
• The agreement between Flowr Corporation and Shoppers Drug Mart is expected to solidify Flowr’s leading position in the Canadian medicinal cannabis market
• Flowr is already a leader in terms of high yields and low production costs – two factors that are proving to be determining for the success of cannabis companies

FlowrRX products by The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) are now available for purchase through the Shoppers Drug Mart online medical cannabis platform, as the company announced on March 18, 2019 (http://ibn.fm/rV9dS).

The two companies confirmed a sales agreement at the beginning of 2019. Through the partnership, The Flowr Corporation and Shoppers Drug Mart are simplifying the delivery of medical cannabis products in Canada.

“Flowr’s premium medical cannabis is grown in what we believe is the industry’s most advanced GMP designed cultivation facility. This relationship is testament to our commitment to ultra-high-quality cannabis cultivation and further solidifies Flowr’s role in Canada’s medical cannabis landscape,” co-CEO Vinay Tolia said in a news release.

To order FlowerRX products, patients are required to submit a completed medical document from a health care practitioner to Shoppers Drug Mart. Company advisers will next contact the health care practitioner to verify the document and ensure the immediate completion of the order.

Previously, FlowrRX products were available via the Flowr online store. As per a 2019 agreement, Shoppers Drug Mart is now the exclusive direct-to-patient distributor of FlowrRX products.

Featuring premium quality medicinal cannabis, the FlowrRX range of offerings is the result of Flowr Corporation’s research and development team focusing on innovative cultivars and the creation of unique products. High quality customer service is another key to the delivery of reliable solutions under the FlowrRX brand.

The FlowrRX premium product delivery program incorporates the use of multiple strains ranging from high THC to more balanced options and featuring the company’s BC Delahaze. Delahaze is an award-winning cultivar known for the strong invigorating effect. The cultivar is grown in the Flowr Corporation’s indoor facility to put emphasis on both potency and flavor through consistent control over the cultivation process.

Flowr Corporation is a Health Canada Licensed Producer of cannabis under the Access to Cannabis for Medical Purposes Regulations. The company is emerging as a Canadian leader in the field as a result of its highly advanced, purpose-built cultivation facilities.

Through its innovative cultivation practices, Flowr consistently generates the high crop yields needed for the delivery of premium and ultra-premium cannabis products.

Control over cultivation and innovative practices result in a cost-efficient cultivation process. As the company notes, high yields per square foot are key to ensuring low operating costs and profitability.

For more information, visit the company’s website at www.Flowr.ca

NOTE TO INVESTORS: The latest news and updates relating to FLPWF are available in the company’s newsroom at http://ibn.fm/FLWPF